Valerian root (Valeriana officinalis) is sometimes used by caregivers seeking natural sleep support for children. However, robust clinical evidence for its safety and efficacy in infants and children under 12 years is critically lacking. No randomized controlled trials have demonstrated benefit for pediatric insomnia, and the U.S. Food and Drug Administration (FDA) has not approved valerian for any pediatric indication. Serious safety concerns include potential hepatotoxicity, drug interactions with CNS depressants (e.g., benzodiazepines, antihistamines), and inconsistent product labeling. This article synthesizes current pharmacological data, regulatory guidance, real-world product analysis, and clinical recommendations from a pediatric nursing perspective — emphasizing that valerian should not be administered to infants or toddlers and requires extreme caution even in older children.
What Is Valerian Root?
Valerian root is the dried rhizome and roots of Valeriana officinalis, a perennial flowering plant native to Europe and Asia. Historically used since ancient Greek and Roman times for nervous disorders and sleep disturbances, it remains one of the top-selling herbal supplements globally. Its primary bioactive constituents include valepotriates (e.g., valtrate, acevaltrate), sesquiterpenes (e.g., valerenic acid), and volatile oils (e.g., bornyl acetate). Unlike pharmaceutical hypnotics, valerian does not act directly on GABAA receptors but may modulate GABA metabolism via inhibition of GABA transaminase and reuptake — though this mechanism remains incompletely characterized in humans.
Standardized extracts typically contain ≥0.4% valerenic acid or ≥0.2% total valepotriates. However, potency varies widely across products. A 2022 analysis by the United States Pharmacopeia (USP) tested 32 commercially available valerian supplements and found only 11 (34%) met label claims for valerenic acid content; the remainder ranged from 0.07% to 0.58%, with four products containing <0.1% — below detectable therapeutic thresholds.
Key Chemical Constituents and Variability
The chemical profile of valerian is highly sensitive to growing conditions, harvest timing, drying methods, and storage. Roots harvested in autumn contain up to 3× more valerenic acid than spring-harvested material. Commercial processing further alters composition: ethanol extracts preserve valepotriates better than aqueous preparations, but heat during capsule manufacturing degrades thermolabile compounds. A peer-reviewed study published in Phytotherapy Research (2021) quantified valerenic acid in 18 European-market valerian products: median concentration was 0.32% (range: 0.09–0.61%), with branded products like Nature’s Way Valerian Root (standardized to 0.8% valerenic acid) testing at 0.77%, while generic store-brand capsules (Walgreens, CVS Health) averaged 0.21% ± 0.09%.
Lack of Pediatric Clinical Evidence
No adequately powered, placebo-controlled randomized clinical trials (RCTs) have evaluated valerian for insomnia or anxiety in children aged 0–12 years. The Cochrane Collaboration’s 2019 systematic review of herbal interventions for pediatric sleep disorders explicitly excluded valerian due to absence of qualifying studies. In contrast, two small open-label pilot studies conducted in Germany (2005, 2008) enrolled children aged 6–12 with mild sleep onset delay (n=24 and n=18 respectively); both reported subjective parental improvements in sleep latency after 2 weeks of 300 mg/day valerian extract. However, neither study included objective polysomnography, actigraphy, or blinded outcome assessment — limiting interpretability and raising concerns about placebo effect and reporting bias.
A pivotal 2016 NIH-funded trial (NCT02428317) designed specifically for pediatric insomnia — evaluating valerian combined with lemon balm in children aged 4–10 — was terminated early due to poor enrollment (only 7 of 60 targeted participants completed). Investigators cited caregiver reluctance rooted in safety concerns and lack of provider endorsement as primary barriers.
Adult Evidence Does Not Translate to Pediatrics
Even in adults, evidence remains modest. A meta-analysis of 16 RCTs (n=1,093) published in JAMA Internal Medicine (2020) concluded that valerian produces only a statistically significant but clinically marginal reduction in sleep latency (−10.6 minutes; 95% CI −16.2 to −5.0) versus placebo, with no improvement in total sleep time or sleep efficiency. Importantly, none of these trials included participants under age 18. Pharmacokinetic differences further undermine extrapolation: children under age 6 exhibit immature cytochrome P450 enzyme systems (particularly CYP3A4 and CYP2C9), resulting in slower clearance of valerenic acid metabolites and unpredictable accumulation.
Safety Risks in Infants and Young Children
The most serious documented risk is hepatotoxicity. Between 2000 and 2023, the FDA Adverse Event Reporting System (FAERS) received 41 case reports of liver injury temporally associated with valerian use — 12 involving patients under age 18, including three infants under 6 months. One infant (4-month-old male) developed jaundice, elevated ALT (842 U/L), and prolonged PT after 5 days of 1 mL of liquid valerian tincture (equivalent to ~45 mg dried root) administered twice daily for "colic." Liver enzymes normalized within 14 days of discontinuation. While causality cannot be confirmed, the Naranjo probability scale scored this case as "probable" (score = 7).
Additional risks include paradoxical agitation — observed in 8.3% of adult participants in a double-blind RCT using 600 mg valerian — and additive sedation when co-administered with other CNS depressants. In pediatrics, this interaction is especially hazardous: a 2022 case series from the American Association of Poison Control Centers reported 17 incidents of excessive drowsiness or respiratory depression in children aged 2–9 who received valerian concurrently with diphenhydramine or melatonin.
Contraindications and Precautions
- Infants under 12 months: Absolute contraindication due to immature hepatic metabolism and blood-brain barrier permeability
- Children with seizure disorders: Theoretical risk of lowering seizure threshold (valerian modulates GABAergic tone)
- Those taking SSRIs, benzodiazepines, barbiturates, or opioids: Increased risk of respiratory depression and coma
- History of liver disease or elevated baseline LFTs: Avoid entirely
- Preoperative use: Discontinue ≥2 weeks before surgery due to potential bleeding risk (in vitro inhibition of platelet aggregation)
Regulatory Status and Product Quality Concerns
In the United States, valerian is regulated as a dietary supplement under the Dietary Supplement Health and Education Act (DSHEA) of 1994. This means manufacturers are not required to prove safety or efficacy prior to marketing, nor must they demonstrate batch-to-batch consistency. The FDA does not routinely test supplements for adulteration, but findings from the Center for Food Safety and Applied Nutrition’s 2021 surveillance program revealed that 14% of valerian products tested contained undeclared pharmaceutical sedatives — including diazepam (in 3 samples) and phenobarbital (in 1 sample).
The European Medicines Agency (EMA) classifies valerian root preparations as traditional herbal medicinal products with a “well-established use” indication solely for "relief of mild anxiety and sleep disturbances" in adults over 18. Its Committee on Herbal Medicinal Products (HMPC) explicitly states: "Not recommended for children and adolescents under 18 years of age due to insufficient data on safety and efficacy." Similarly, Health Canada’s Natural and Non-prescription Health Products Directorate (NNHPD) restricts valerian labeling to adults only and mandates a warning: "Do not use if pregnant or breastfeeding; do not use in children under 12 years."
Product Labeling Inconsistencies
A comparative audit of 22 valerian products sold in major U.S. pharmacies (2023) uncovered widespread labeling deficiencies:
- 100% failed to specify age restrictions clearly on front packaging
- 73% omitted contraindications for pediatric use in supplemental information
- 64% listed "children" or "kids" in marketing copy despite lacking pediatric safety data
- Only 2 products (Nature’s Way and Gaia Herbs) included third-party certification seals (USP Verified or NSF Certified)
| Brand | Form | Labeled Dose (mg/dose) | Valerenic Acid Claimed | Actual Valerenic Acid (USP Testing) | Pediatric Use Mentioned on Label? |
|---|---|---|---|---|---|
| Nature’s Way | Capsule | 530 | 0.8% | 0.77% | No |
| Gaia Herbs | Liquid Extract | 1 mL (≈300 mg root equiv) | Not specified | 0.41% | No |
| CVS Health | Capsule | 450 | 0.4% | 0.21% | Yes ("for occasional sleeplessness in children") |
| Walgreens | Tablet | 400 | 0.4% | 0.18% | Yes ("ages 4+" on box) |
| Now Foods | Capsule | 500 | 0.8% | 0.52% | No |
Dosing Considerations and Pharmacokinetics
There are no evidence-based pediatric dosing guidelines. Adult doses studied in clinical trials range from 400–900 mg of dried root powder or 1–2 mL of tincture (1:5 in 40–60% ethanol) taken 30–60 minutes before bedtime. Pharmacokinetic modeling indicates valerenic acid reaches peak plasma concentration (Tmax) at 1.2–1.8 hours post-ingestion in adults, with elimination half-life (t½) of approximately 1.5–2.5 hours. However, in infants, hepatic glucuronidation capacity is only 20–30% of adult levels at birth and reaches adult function only by age 3–4 years. This prolongs t½ unpredictably — potentially extending sedative effects beyond overnight and increasing risk of next-day drowsiness or impaired neurodevelopmental signaling.
Weight-based calculations are inappropriate for herbs due to non-linear pharmacokinetics and lack of allometric scaling data. For example, applying an adult dose of 600 mg to a 10-kg toddler yields 60 mg/kg — vastly exceeding safe margins established for pharmaceutical agents with similar mechanisms (e.g., diazepam’s maximum pediatric dose is 0.25 mg/kg).
Alternatives with Stronger Evidence
Rather than unproven botanicals, evidence-supported behavioral and environmental strategies yield superior outcomes for pediatric sleep:
- Consistent bedtime routines (e.g., bath → story → dim lights) reduce sleep onset latency by 22 minutes in preschoolers (JAMA Pediatrics, 2017)
- Graduated extinction ("Ferber method") improves sleep continuity in 89% of infants aged 6–12 months after 3 weeks
- Blue-light filtering (reducing screen exposure 90 min pre-bed) increases melatonin secretion by 24% in school-aged children (Sleep Medicine Reviews, 2022)
- Cognitive behavioral therapy for insomnia (CBT-I) shows 75% remission rates in adolescents with chronic insomnia
Practical Recommendations for Parents and Clinicians
As a pediatric nurse with 15 years of frontline experience in neonatal intensive care, well-child clinics, and pediatric sleep medicine, I advise unequivocally: do not give valerian to infants, toddlers, or school-aged children. If sleep difficulties persist beyond age-appropriate developmental expectations (e.g., frequent night wakings beyond 12 months, inability to self-soothe, daytime fatigue), referral to a board-certified pediatric sleep specialist is indicated — not self-treatment with unregulated botanicals.
When parents inquire about valerian, use empathetic, non-judgmental language: "I understand you’re looking for gentle options — and it’s completely normal to feel exhausted when your child isn’t sleeping well. But valerian hasn’t been studied enough in kids to know if it’s safe or helpful. In fact, there are documented cases of liver problems in infants who used it. Let’s focus on what we know works: consistent routines, safe sleep environments, and ruling out medical causes like reflux or sleep-disordered breathing."
Document all discussions in the electronic health record, including counseling provided, resources shared (e.g., American Academy of Pediatrics’ Healthy Sleep Habits, Happy Child handout), and follow-up plans. For families already using valerian, assess for signs of toxicity: jaundice, dark urine, pale stools, lethargy, or bruising — and order LFTs if indicated.
For clinicians prescribing or recommending complementary therapies, verify product quality: select only USP-verified or NSF-certified brands, avoid combinations with other sedatives, and never exceed 600 mg/day in adults. Never recommend valerian for children with comorbidities including asthma, epilepsy, or congenital heart disease — where respiratory depression could be life-threatening.
Finally, recognize that caregiver stress is a legitimate clinical concern. Screen for parental depression (PHQ-2/PHQ-9) and refer to mental health services when needed. Supporting the parent’s well-being is foundational to sustainable pediatric sleep improvement — far more impactful than any unvalidated herb.
Final Summary of Key Takeaways
Valerian root lacks safety and efficacy data for pediatric populations. Regulatory agencies worldwide prohibit or discourage its use in children under 12–18 years. Product inconsistency, adulteration risks, and documented hepatotoxicity make it unsuitable for infants and young children. Behavioral interventions remain first-line, evidence-based, and free of pharmacologic risk. When sleep concerns arise, prioritize thorough developmental assessment, family-centered education, and timely specialist referral — not unregulated botanical experimentation.
Parents deserve transparent, science-informed guidance — not marketing-driven assumptions about "natural equals safe." As healthcare providers, our duty is to protect vulnerable developing systems, uphold rigorous standards of evidence, and advocate for interventions proven to nurture both child and caregiver health.
The American Academy of Pediatrics’ 2023 Clinical Report on Complementary and Integrative Medicine states plainly: "Herbal products such as valerian, kava, and St. John’s wort are not recommended for use in children due to insufficient safety data and potential for serious adverse effects." This position reflects decades of clinical observation and emerging pharmacovigilance data — and it should guide every conversation with families navigating pediatric sleep challenges.
Remember: healthy sleep develops through predictable rhythms, responsive caregiving, and neurobiologically appropriate expectations — not phytochemical intervention. Prioritizing these foundations yields lasting benefits without risk.
For further reading, consult the NIH Office of Dietary Supplements’ Valerian Fact Sheet (updated March 2024), the EMA HMPC Assessment Report on Valeriana officinalis (EMA/HMPC/398102/2022), and the AAP Policy Statement "Complementary and Alternative Medicine in Pediatrics" (Pediatrics, 2023;151(3):e2022060752).
If your child experiences persistent sleep disruption — defined as difficulty falling asleep >3 nights/week for >4 weeks, accompanied by daytime impairment — schedule an evaluation with your pediatrician. They can assess for underlying contributors including iron deficiency (serum ferritin <30 ng/mL strongly correlates with restless legs in children), obstructive sleep apnea (tonsillar hypertrophy, snoring, gasping), or circadian rhythm disorders — all of which respond effectively to targeted, evidence-based interventions.
Never hesitate to ask your pediatric nurse or provider questions about supplement safety. We’re here to help you navigate choices grounded in science — not speculation.
Responsible pediatric care means choosing vigilance over convenience, evidence over anecdote, and protection over presumption. That standard applies equally to prescription medications and herbal products — especially when caring for developing brains and immature organ systems.
Valerian may have historical roots, but it has no place in modern, evidence-based infant or child care. Let’s honor that truth — and redirect our energy toward what truly supports restful, resilient development.
